{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:13:27Z","timestamp":1694826807352},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.ygyno.2008.08.005","type":"journal-article","created":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T08:51:23Z","timestamp":1222937483000},"page":"467-473","source":"Crossref","is-referenced-by-count":4,"title":["Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer"],"prefix":"10.1016","volume":"111","author":[{"given":"Thomas J.","family":"Herzog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet S.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall K.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Lippmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2008.08.005_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2008.08.005_bib2","series-title":"Clinical Gynecologic Oncology","author":"DiSaia","year":"2002"},{"key":"10.1016\/j.ygyno.2008.08.005_bib3","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment or recurrent ovarian cancer","volume":"15","author":"Ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.08.005_bib4","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.08.005_bib5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/gyno.1997.4787","article-title":"Topotecan in platinum and paclitaxel-resistant ovarian cancer","volume":"66","author":"Swisher","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.08.005_bib6","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.08.005_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/gyno.2000.5844","article-title":"A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2008.08.005_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ygyno.2004.09.005","article-title":"Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer","volume":"95","author":"Levy","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2008.08.005_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ygyno.2006.04.014","article-title":"Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer","volume":"103","author":"Herzog","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2008.08.005_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/gyno.1998.5243","article-title":"Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer","volume":"72","author":"Burger","year":"1999","journal-title":"Gynecol Oncol"},{"issue":"2 Suppl","key":"10.1016\/j.ygyno.2008.08.005_bib11","first-page":"37","article-title":"Safety and tolerance of navelbine in phase I\u2013II clinical studies","volume":"6","author":"Besenval","year":"1989","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2008.08.005_bib12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2165\/00002512-199405030-00006","article-title":"Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy","volume":"5","author":"Goa","year":"1994","journal-title":"Drugs Aging"},{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2008.08.005_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000055390","article-title":"Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I\/II trial with topotecan and vinorelbine","volume":"61","author":"Stupp","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2008.08.005_bib14","unstructured":"Vivacqua RJ, Lebedda J, Keogh W, Soojian M. Phase I\/II study of sequential interferon alpha-2b (IFN-\u03b12b) and weekly topotecan\/vinorelbine in advanced non-small cell lung cancer (NSCLC) Abstract - 2721 Proceedings ASCO, 2002."},{"issue":"3","key":"10.1016\/j.ygyno.2008.08.005_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejpb.2006.10.007","article-title":"In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine","volume":"65","author":"Webb","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"issue":"20","key":"10.1016\/j.ygyno.2008.08.005_bib16","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/jnci\/86.20.1517","article-title":"Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design","volume":"86","author":"Chou","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ygyno.2008.08.005_bib17","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2000.18.8.1733","article-title":"Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials","volume":"18","author":"Rustin","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.08.005_bib18","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1158\/1078-0432.CCR-04-0683","article-title":"Recurrent ovarian cancer: how important is it to treat to disease progression?","volume":"10","author":"Herzog","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ygyno.2008.08.005_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11912-006-0074-9","article-title":"The current treatment of recurrent ovarian cancer","volume":"8","author":"Herzog","year":"2006","journal-title":"Curr Oncol Rep"},{"issue":"9375","key":"10.1016\/j.ygyno.2008.08.005_bib21","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Parmar, M.K., et al., Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2008.08.005_bib22","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine\/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580800632X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580800632X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T11:01:09Z","timestamp":1557831669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082580800632X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S009082580800632X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.08.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}